Cardiovascular Benefits of Empagliflozin Are Associated With Gut Microbiota and Plasma Metabolites in Type 2 Diabetes.
Deng X, Zhang C, Wang P, Wei W, Shi X, Wang P, Yang J, Wang L, Tang S, Fang Y, Liu Y, Chen Y, Zhang Y, Yuan Q, Shang J, Kan Q, Yang H, Man H, Wang D, Yuan H.
Deng X, et al. Among authors: wei w.
J Clin Endocrinol Metab. 2022 Jun 16;107(7):1888-1896. doi: 10.1210/clinem/dgac210.
J Clin Endocrinol Metab. 2022.
PMID: 35397165
Free PMC article.
Clinical Trial.